Medicure Inc. (CVE:MPH – Get Free Report)’s stock price reached a new 52-week high on Tuesday . The company traded as high as C$2.74 and last traded at C$2.74, with a volume of 900 shares traded. The stock had previously closed at C$2.69.
Medicure Price Performance
The company has a quick ratio of 1.28, a current ratio of 0.97 and a debt-to-equity ratio of 6.02. The business’s 50-day simple moving average is C$1.69 and its 200 day simple moving average is C$1.33. The firm has a market capitalization of C$28.59 million, a P/E ratio of -3.81 and a beta of 0.93.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
See Also
- Five stocks we like better than Medicure
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
- IonQ’s AI Breakthrough Looks Big—But Can It Drive Revenue?
- Broadcom CEO Holds $350B Outlook Strong Amid Calls to Slow Froniter AI Development
- Microsoft’s 8% Dividend Hike: Confidence Signal or Distraction From Capex Math?
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
